|
A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation. |
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Parthenon Therapeutics |
Honoraria - Agenus; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Elevation Oncology; Incendia Therapeutics; Loxo/Lilly; Macrogenics; Regeneron; Seagen; Taiho Oncology |
|
|
Research Funding - Abbvie (Inst); Alliance Foundation Trials (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Huntsman Cancer Institute (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Syneos Health (Inst); Tesaro (Inst) |
|
Thorvardur Ragnar Halfdanarson |
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Tersera; Viewpoint Molecular Targeting (Inst) |
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Perspective Therapeutics (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst) |
(OPTIONAL) Uncompensated Relationships - North American Neuroendocrine Tumor Society |
|
|
|
Research Funding - Lilly (Inst); Taiho Oncology (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Five Prime Therapeutics |
Consulting or Advisory Role - Abbvie; ABL Bio; Actuate Therapeutics; Agenus; Amgen; AstraZeneca; Atreca; BAKX Therapeutics; Boehringer Ingelheim; Compass Therapeutics; Cullinan Oncology; DAAN Biotherapeutics; EMD Serono; GlaxoSmithKline; I-Mab; ImCheck therapeutics; IQvia; Kineta; Kyowa Kirin International; Mekanistic Therapeutics; Mersana; Molecular Templates; Neurotrials Research; Pfizer; QED Therapeutics; Qualigen Therapeutics; Quanta Therapeutics; Relay Therapeutics; Roche/Genentech; Roivant; Scenic Biotech; Schrodinger; Seagen; Sotio; ST Cube; Stemline Therapeutics; Takeda; Zentalis |
Research Funding - Genentech (Inst) |
Travel, Accommodations, Expenses - Genentech |
|
|
Employment - AstraZeneca; Cullgen |
Consulting or Advisory Role - Cancer Expert Now |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer Health; Bexion; BioSapien; Bristol-Myers Squibb/Celgene; insmed; ipsen; Mekanistic Therapeutics; Merck; Merck KGaA; Merus; Mirati Therapeutics; Oxford BioTherapeutics |
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); hibercell (Inst); I-MAB (Inst); Incendia Pharmaceuticals AB (Inst); Incyte (Inst); Lilly (Inst); ribosciences (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst); Volastra Therapeutics (Inst) |
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure |
|
|
Employment - Voisin Consulting (I) |
Stock and Other Ownership Interests - GlaxoSmithKline (I) |
Research Funding - TriSalus Life Sciences (Inst) |
Patents, Royalties, Other Intellectual Property - Sulphoraphane for melanoma chemoprevention (Inst) |
Expert Testimony - Astellas Pharma; AstraZeneca/Merck |
(OPTIONAL) Uncompensated Relationships - Applied Isotope Technologies; Qrono |
|
|
|
Consulting or Advisory Role - AstraZeneca; Eisai; Elevar Therapeutics; Primum |
Travel, Accommodations, Expenses - Eisai |